
Progenics (NASDAQ:PGNX)
Progenics (NASDAQ:PGNX)
Progenics (NASDAQ:PGNX) reported Q2 EPS and incomes in front of perspectives, and it was not because of superior to anything expected Relistor sovereignties. The organization perceived a $4 million point of reference installment from Bayer (OTCPK:BAYRY) for the PSMA Antibody Technology permit. This cooperation could open some shareholder esteem in the next years. News broke a week ago that Relistor is drawing some purchaser interest and that Valeant (NYSE:VRX) may offer its rights to the most noteworthy bidder.
A $400-500 million sticker price was specified in the Bloomberg article. The inferred cost allots little esteem to Relistor considering